Analysis Tools
cellular
|
• three fold increase in micronuclei and nucleoplasmic bridges after etoposide treatment as compared to controls
|
|
• three fold increase in chromosomal aberrations after etoposide treatment as compared to controls
• increased number of chromosomal breaks and exchanges in metaphase spreads of mice treated with etoposide
|
|
• three fold increase in micronuclei and nucleoplasmic bridges after etoposide treatment as compared to controls
|
|
• severe reduction of metaphase spreads in cultured embryonic fibroblasts treated with etoposide
|
homeostasis/metabolism
|
• are hypersensitive to etoposide damage but sensitivity is normal to gamma radiation
|
growth/size/body
|
• etoposide causes a progressive and severe weight loss unlike the transient weight loss seen in controls
|
digestive/alimentary system
|
• villous atrophy 6 days after treatment with etoposide
|
hematopoietic system
|
• reduced cellular content after etoposide treatment
|
|
• 30-50% loss of pro-B cells, 95%loss of pre-B cells and immature B cell precursors
• losses are not significantly different from controls similarly treated with etoposide
|
|
• almost completely eliminated by etoposide treatment
|
|
• two fold increase relative to controls in micronucleated polychromatic erythrocytes in bone marrow from etoposide treated mice
|
|
• reduced cellular content after etoposide treatment
|
immune system
|
• 30-50% loss of pro-B cells, 95%loss of pre-B cells and immature B cell precursors
• losses are not significantly different from controls similarly treated with etoposide
|
|
• almost completely eliminated by etoposide treatment
|
|
• reduced cellular content after etoposide treatment
|
|
• reduced cellular content after etoposide treatment
|
endocrine/exocrine glands
|
• reduced cellular content after etoposide treatment
|
